Retail sales of Tylenol remain broadly steady across global markets even as the brand faces mounting political and legal scrutiny.
In recent months, remarks from US President Donald Trump and several of his allies alleging a link between Tylenol use during pregnancy and autism have reignited safety debates surrounding the popular over-the-counter (OTC) pain reliever.
The claims, dismissed by medical experts and regulators, briefly unsettled investors and fuelled online discussion, but early retail indicators suggest limited long-term impact on consumer demand.
Kenvue, Tylenol’s parent company, does not publish brand-specific figures, but analysts estimate annual Tylenol sales at roughly US$1 billion. The brand sits within Kenvue’s Self Care division, which posted organic growth of 1.7 per cent in the final quarter of 2024 and total net sales of US$15.5 billion for the year.
Those results underline continued strength in the company’s OTC portfolio despite reputational turbulence.
In September 2025, Trump used a campaign event and social-media posts to suggest that Tylenol could cause autism when taken during pregnancy. The allegations were unsupported by scientific evidence but spread rapidly online, amplified by political commentators and sympathetic media figures.
Shares in Kenvue fell to a record low the following day as retail investors reacted to the headlines before rebounding once analysts and health authorities reaffirmed that no causal link had been established.
For retailers, the episode highlighted how politically driven health narratives can momentarily affect consumer sentiment and brand perception.
Industry analysts noted a brief dip in Nielsen scanner data following the controversy, particularly in the United States, though sales largely normalised within weeks as coverage subsided.
Beyond the political noise, Kenvue and its former parent Johnson & Johnson face hundreds of lawsuits alleging that prenatal acetaminophen exposure causes neurodevelopmental disorders such as autism and ADHD.
Most scientific reviews, including those referenced by US and European regulators, have found the evidence inconclusive. Nevertheless, the cases continue to generate headlines.
On 28 October 2025, the Texas Attorney General sued both companies, claiming they misled pregnant consumers about potential risks. Kenvue has denied wrongdoing, calling its product safe when used as directed.
Legal experts say the litigation could take years to resolve and is unlikely to lead to immediate product removals, but ongoing attention may shape consumer choices and push some shoppers toward alternatives such as ibuprofen or private-label paracetamol.
Source link